Ocugen, Inc. (OCGN) Stock Forecast & Price Target

Ocugen is viewed favorably because its pipeline spans multiple high-need ophthalmology programs, with OCU400 in retinitis pigmentosa, OCU410 in geographic atrophy, and OCU410ST in Stargardt disease all supported by encouraging clinical data and alignment with FDA guidance. The company has meaningful catalysts ahead, including 1Q27 topline data for OCU400, a potential 2H26 pivotal start for OCU410, and near-term regulatory interactions, while the 140-patient OCU400 study and 300-patient OCU410 trial design suggest substantial development scale. Financially, the recent debt offering extends runway into 2028, net proceeds were about $80M after retiring Avenue debt, and additional upside may come from Janus Henderson warrant exercise, a Stargardt Priority Review Voucher, and partnership funding.

Ocugen is facing a weaker fundamental setup because the independent data monitoring committee’s interim review of GARDian3 found a negative direction of treatment effect, even as it recommended continuing the study to gather full 8-month follow-up data from all 63 enrolled subjects. That mixed outcome increases execution risk for OCU410ST in Stargardt disease, especially since management has not yet disclosed its regulatory strategy and the company’s own data suggest approval could be delayed beyond 2028, with launch now conservatively pushed to 2030 from 2028. The setback matters further because Stargardt is the smallest addressable opportunity among the gene therapy programs, with about 100K patients in the US and EU versus 300K for RP and 2-3M for GA, limiting near-term commercial upside.